Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MEMANTINE HCL

All products: not a benefit

Apo-Memantine · DIN 02366487 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Memantine · DIN 02366487 Manufacturer: Apotex Inc.; listing date 2011-12-15 Health Canada: Marketed since 2020-05-25 · brand APO-MEMANTINE · ATC N06DX01 MEMANTINE · form Tablet · route Oral · ingredients MEMANTINE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85130 · Verify on the e-Formulary ↗ (DIN 02366487)

Source record
DIN 02366487: Apo-Memantine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200037; group id 540; item number 1458; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.6357; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02366487 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85130
Interchangeable products
Act Memantine · DIN 02324067 · not recorded Ebixa · DIN 02260638 · not recorded Jamp-Memantine · DIN 02409895 · not recorded Memantine · DIN 02443082 · not recorded Memantine · DIN 02446049 · not recorded Mint-Memantine · DIN 02531887 · not recorded PMS-Memantine · DIN 02321130 · not recorded Ran-Memantine · DIN 02421364 · not recorded Ratio-Memantine · DIN 02320908 · not recorded Sandoz Memantine FCT · DIN 02375532 · not recorded
Shortage status: resolved shortage (ended 2022-10-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02366487
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 37 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATION AND CLINICAL USE pms-MEMANTINE (memantine hydrochloride) may be useful as monotherapy or as adjunctive therapy with cholinesterase inhibitors1 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer’s type. pms-MEMANTINE tablets should only be prescribed by (or following consultation with) clinicians who are experienced in the diagnosis and management of Alzheimer’s disease. In a 28-week placebo controlled monotherapy trial, patients with moderate to severe Alzheimer’s disease showed stabilization or less worsening of functional and cognitive symptoms and of global assessment when treated with memantine hydrochloride compared to placebo. In a 24 week “add-on” placebo controlled trial in which patients were treated with either memantine hydrochloride or placebo as add-on to ongoing donepezil therapy, stabilization or less worsening of functional and cognitive symptoms and of global assessment was observed in patients with moderate to severe Alzheimer’s disease when treated with memantine hydrochloride compared to placebo. 1 Cholinesterase inhibitors refers to only those which are approved in Canada … https://pdf.hres.ca/dpd_pm/00034930.PDF PM date: May 10, 2016 Source product: PMS-MEMANTINE; DIN 02321130; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Apo-Memantine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026